<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Onkure Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/onkure-therapeutics-inc</link>
<description>Latest news and press releases for Onkure Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 05 May 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/onkure-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a65678dffbe2df10b7ad.webp</url>
<title>Onkure Therapeutics, Inc.</title>
<link>https://6ix.com/company/onkure-therapeutics-inc</link>
</image>
<item>
<title>OnKure Therapeutics Reports First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-first-quarter-2026-financial-results</guid>
<pubDate>Tue, 05 May 2026 20:05:00 GMT</pubDate>
<description>-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company’s pipeline in vascular anomalies -- Announced nomination of OKI-345, a next generation PI3Kα pan-mutant selective inhibitor candidate, in breast cancer -- Closed $150 million private placement to advance next-generation PI3Kα pan-mutant programs into clinical development in 2027 -- $192 million cash and cash eq</description>
</item>
<item>
<title>OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-announces-oversubscribed-dollar150-million-private-placement-to-advance-next-generation-pi3ka-pan-mutant-selective-inhibitor-candidates-in-breast-cancer-and-vascular-anomalies</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-announces-oversubscribed-dollar150-million-private-placement-to-advance-next-generation-pi3ka-pan-mutant-selective-inhibitor-candidates-in-breast-cancer-and-vascular-anomalies</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα</description>
</item>
<item>
<title>OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-1</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations -- Next-generation PI3Kα pan-mutant inhibitor development candidate for HR+ metastatic breast cancer is expected to be announced in March 2026 -- Approximately $59M in cash and cash equivalents at the end of Q4 2025 BOULDER, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focu</description>
</item>
<item>
<title>OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-third-quarter-210300788</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-third-quarter-210300788</guid>
<pubDate>Thu, 06 Nov 2025 21:03:00 GMT</pubDate>
<description>-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next-generation P</description>
</item>
<item>
<title>OnKure Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-participate-upcoming-investor-210500343</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-participate-upcoming-investor-210500343</guid>
<pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
<description>BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Guggenheim Healthcare Innovation Conference, in Boston on Monday, November 10, 2025, at 4:00 p.m</description>
</item>
<item>
<title>OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-second-quarter-200500265</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-second-quarter-200500265</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic breast cancer -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with trastuzumab and tucatinib in HER2+ metastatic breast cancer -- Cash pos</description>
</item>
<item>
<title>OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-first-quarter-113000640</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-first-quarter-113000640</guid>
<pubDate>Tue, 06 May 2025 11:30:00 GMT</pubDate>
<description>-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company’s PI3Ka franchise with the planned announcement of a pan-mutant selective development candidate in Q2 2025 -- $96.7M in cash and cash equivalents expected to be sufficient to fund operations through multiple anticipated milestones into Q4 2026 BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- OnKure The</description>
</item>
<item>
<title>OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-fourth-quarter-200500107</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-reports-fourth-quarter-200500107</guid>
<pubDate>Mon, 10 Mar 2025 20:05:00 GMT</pubDate>
<description>— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 — Expansion of PI3Ka franchise to include a pan-mutant selective program; development candidate expected to be announced in Q2 2025 — $111M in cash and cash equivalents expected to be sufficient to fund operations through multiple PIKture-01 clinical readouts and anticipated milestones into Q4 2026 BOU</description>
</item>
<item>
<title>OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-present-upcoming-leerink-130000581</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-therapeutics-present-upcoming-leerink-130000581</guid>
<pubDate>Tue, 04 Mar 2025 13:00:00 GMT</pubDate>
<description>BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Leerink Partners Global Healthcare Conference, in Miami on Tuesday, March</description>
</item>
<item>
<title>OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-announces-encouraging-preliminary-safety-tolerability-and-pharmacokinetic-pk-data-from-its-first-in-human-pikture-01-trial-of-oki-219</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-announces-encouraging-preliminary-safety-tolerability-and-pharmacokinetic-pk-data-from-its-first-in-human-pikture-01-trial-of-oki-219</guid>
<pubDate>Tue, 10 Dec 2024 05:00:00 GMT</pubDate>
<description>-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show</description>
</item>
<item>
<title>OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-to-present-clinical-and-preclinical-data-for-oki-219-at-the-2024-san-antonio-breast-cancer-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-to-present-clinical-and-preclinical-data-for-oki-219-at-the-2024-san-antonio-breast-cancer-symposium</guid>
<pubDate>Fri, 01 Nov 2024 04:00:00 GMT</pubDate>
<description>OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET</description>
</item>
<item>
<title>OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/onkure-announces-closing-of-merger-with-reneo-pharmaceuticals-and-concurrent-private-placement-of-dollar65-million</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/onkure-announces-closing-of-merger-with-reneo-pharmaceuticals-and-concurrent-private-placement-of-dollar65-million</guid>
<pubDate>Fri, 04 Oct 2024 04:00:00 GMT</pubDate>
<description>-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast</description>
</item>
<item>
<title>Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-appoints-roshawn-blunt-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-appoints-roshawn-blunt-to-its-board-of-directors</guid>
<pubDate>Tue, 02 Aug 2022 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the</description>
</item>
<item>
<title>Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-announces-notice-of-allowance-for-patent-application-on-ren001</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-announces-notice-of-allowance-for-patent-application-on-ren001</guid>
<pubDate>Thu, 14 Oct 2021 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the</description>
</item>
<item>
<title>Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Thu, 09 Sep 2021 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the</description>
</item>
<item>
<title>Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-reports-second-quarter-2021-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-reports-second-quarter-2021-financial-results</guid>
<pubDate>Wed, 11 Aug 2021 04:00:00 GMT</pubDate>
<description>First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals,</description>
</item>
<item>
<title>Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-announces-first-patient-dosed-in-the-stride-study</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-announces-first-patient-dosed-in-the-stride-study</guid>
<pubDate>Wed, 28 Jul 2021 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the</description>
</item>
<item>
<title>Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-announces-partial-waiver-of-lock-up-restriction</guid>
<pubDate>Fri, 09 Jul 2021 04:00:00 GMT</pubDate>
<description>SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development</description>
</item>
<item>
<title>Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-added-to-the-russell-2000r-and-russell-3000r-indices</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-added-to-the-russell-2000r-and-russell-3000r-indices</guid>
<pubDate>Tue, 29 Jun 2021 04:00:00 GMT</pubDate>
<description>SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development</description>
</item>
<item>
<title>Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference</title>
<link>https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/onkure-therapeutics-inc/news/reneo-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference</guid>
<pubDate>Wed, 19 May 2021 04:00:00 GMT</pubDate>
<description>SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and</description>
</item>
</channel>
</rss>